```html

Xanthogranulomatous Cholecystitis (XGC)

Overview

Xanthogranulomatous cholecystitis (XGC) is a rare, chronic inflammation of the gallbladder characterized by the accumulation of lipid‑laden (xanthoma) macrophages, fibrosis, and thickening of the gallbladder wall. Radiologically and intraoperatively it can mimic gallbladder cancer, making accurate diagnosis essential.

• Typical age: 50–70 years, although cases have been reported in younger adults.
• Gender: Slight male predominance (≈55 % male vs. 45 % female).
• Prevalence: XGC accounts for 0.7–13 % of all cholecystectomies, depending on geographic region and referral pattern (Mayo Clinic; Singh et al., 2020).
• Geography: More frequently reported in Asian and Middle‑Eastern populations, possibly reflecting regional differences in gallstone disease.

Symptoms

Symptoms of XGC overlap with those of typical gallstone disease but are often more protracted because the inflammation is chronic.

Common presenting features

• Right upper‑quadrant (RUQ) abdominal pain: Dull, constant, may radiate to the back or right shoulder.
• Durable dyspepsia: Bloating, early satiety, and a feeling of fullness after small meals.
• Jaundice: Present in 20–30 % of cases when the inflamed gallbladder compresses the common bile duct.
• Fever & chills: Low‑grade fever may indicate superimposed infection.
• Weight loss: Unintentional loss >5 % body weight over 3–6 months (often due to reduced intake from pain).
• Palpable mass: A firm, tender mass in the right upper abdomen can be felt in advanced disease.

Less frequent but noteworthy signs

• Night‑time or post‑prandial epigastric pain.
• Pruritus (itching) secondary to cholestasis.
• Elevated liver enzymes without clear bile duct obstruction.
• Hematemesis or melena if ulceration of the adjacent duodenum occurs—rare but reported.

Causes and Risk Factors

The exact pathogenesis of XGC remains incompletely understood. The prevailing hypothesis involves a cascade that begins with gallstone–induced obstruction and progresses to chronic inflammation.

Primary mechanisms

• Gallstones: Present in up to 90 % of XGC patients; they cause mechanical irritation, mucosal ulceration, and bile stasis.
• Bile extravasation: When the gallbladder wall is breached, bile leaks into the wall, inciting a foreign‑body granulomatous response.
• Foamy macrophage infiltration: Phagocytosis of lipid‑rich bile components leads to xanthoma cells.
• Fibrosis: Ongoing inflammation triggers fibroblast activation and dense wall thickening.

Risk factors

• Chronic cholelithiasis (gallstones) – the strongest association.
• Female sex (related to higher gallstone prevalence).
• Obesity (BMI ≥ 30 kg/m²) – promotes cholesterol stone formation.
• Metabolic syndrome & diabetes mellitus – linked to altered bile composition.
• Previous biliary surgery or endoscopic retrograde cholangiopancreatography (ERCP) – may cause scarring.
• Autoimmune disorders (e.g., primary sclerosing cholangitis) – rare but documented.

Diagnosis

Because XGC can masquerade as gallbladder carcinoma, a multimodal approach is required.

Clinical evaluation

• Detailed history focusing on gallstone disease, pain pattern, and systemic symptoms.
• Physical examination—RUQ tenderness, possible palpable mass, and signs of jaundice.

Laboratory tests

• Complete blood count – may reveal leukocytosis if infection is present.
• Liver function panel – elevated alkaline phosphatase, γ‑GT, and bilirubin in obstructive cases.
• C‑reactive protein (CRP) – nonspecific marker of inflammation.
• Tumor markers (CA‑19‑9, CEA) – usually normal, but elevated levels raise suspicion for malignancy and warrant further work‑up.

Imaging studies

1. Ultrasound (US): First‑line; shows gallbladder wall thickening (>5 mm), intra‑gallbladder echogenic foci, and “hypoechoic nodules” representing xanthoma clusters. Sensitivity ≈85 % for XGC vs. gallstones.
2. Computed Tomography (CT): Provides detailed anatomy; typical findings include:
   • Irregular, thickened gallbladder wall with low‑attenuation (‑20 to +30 HU) intramural nodules.
   • Extensive pericholecystic inflammatory fat stranding.
   • Preservation of the hepatic pedicle (helps differentiate from carcinoma).
3. Magnetic Resonance Cholangiopancreatography (MRCP): Excellent for evaluating bile duct involvement; shows a “halo sign” (high‑signal rim) around the gallbladder.
4. Endoscopic ultrasound (EUS): Highly sensitive for distinguishing XGC from malignancy; allows fine‑needle aspiration (FNA) if needed.

Histopathology (gold standard)

If surgery is performed, the definitive diagnosis rests on microscopic examination:

• Foamy (xanthoma) macrophages within the lamina propria.
• Multinucleated giant cells and chronic inflammatory infiltrates.
• Fibrosis and occasional cholesterol clefts.

Treatment Options

Management is individualized based on disease severity, presence of complications, and patient comorbidities.

1. Surgical treatment – the cornerstone

• Laparoscopic cholecystectomy: Preferred for early‑stage XGC when the gallbladder can be safely dissected. Conversion to open surgery occurs in 15–30 % of cases due to dense adhesions.
• Open cholecystectomy: Recommended when the wall is extensively thickened, there is suspicion of carcinoma, or vascular injury risk is high.
• Extended (partial) hepatic resection: Rare, reserved for cases where XGC infiltrates the liver and mimics cancer.

2. Medical therapy

• Antibiotics: Broad‑spectrum coverage (e.g., ceftriaxone + metronidazole) for patients with documented infection or high fever. Typically 5–7 days pre‑operatively.
• Pain control: NSAIDs (ibuprofen 400 mg tid) or acetaminophen; avoid long‑term NSAID use in patients with peptic ulcer risk.
• Bile‑acid therapy: Ursodeoxycholic acid (UDCA) 300 mg bid may help dissolve cholesterol stones and reduce bile stasis, though evidence in XGC is limited.

3. Lifestyle and supportive measures

• Low‑fat, high‑fiber diet to prevent further stone formation.
• Hydration – at least 1.5–2 L of water per day.
• Weight management – aim for 5‑10 % body‑weight reduction if BMI ≥ 30 kg/m².

Living with Xanthogranulomatous Cholecystitis

Even after successful surgery, long‑term strategies are important to prevent recurrence of gallstone disease and maintain overall health.

Post‑operative care

• Follow surgeon‑provided wound‑care instructions; keep incision clean and dry.
• Gradually resume activity – light walking from day 1, avoid heavy lifting >10 kg for 2–4 weeks.
• Schedule a follow‑up US or CT 6–12 weeks post‑op to ensure no residual wall thickening.

Daily management tips

• Meal timing: Eat smaller, more frequent meals (5–6 times daily) to lessen gallbladder workload.
• Fat intake: Limit saturated fats (<7 % of total calories) and avoid fried foods.
• Physical activity: Aim for ≥150 min of moderate aerobic exercise weekly (e.g., brisk walking, cycling).
• Regular monitoring: Annual liver function tests and abdominal ultrasound if you have a history of stones.

Prevention

Since gallstones are the principal driver, prevention focuses on reducing stone formation.

• Maintain a healthy weight: Weight loss of 0.5–1 kg per week is safe; rapid loss can increase stone risk.
• Dietary recommendations:
  • Increase intake of fruits, vegetables, and whole grains.
  • Consume healthy fats (olive oil, omega‑3 fatty acids) in moderation.
  • Limit cholesterol‑rich foods (red meat, full‑fat dairy).
• Stay hydrated: Dilutes bile salts, lowering cholesterol crystallization.
• Control metabolic conditions: Good glycemic control in diabetes and lipid‑lowering therapy when indicated.
• Avoid prolonged fasting: Skipping meals for >24 hours can precipitate bile stasis.

Complications

If untreated or incompletely treated, XGC can lead to serious sequelae.

• Biliary obstruction: Compression of the cystic duct or common bile duct → jaundice, cholangitis.
• Gallbladder perforation: Rare but life‑threatening; can cause peritonitis.
• Secondary infection: Empyema (pus in the gallbladder) requiring urgent drainage.
• Fistula formation: Cholecysto‑enteric or cholecysto‑cutaneous fistulas develop from chronic inflammation.
• Misdiagnosis as cancer: May lead to unnecessary extensive resections.
• Recurrent stone disease: Persistent risk after cholecystectomy if bile composition remains abnormal.

When to Seek Emergency Care

References

• Singh, A. et al. “Xanthogranulomatous Cholecystitis: Clinicopathological Review.” *World Journal of Gastroenterology*, 2020; 26(14): 1495‑1505. PMID: 32020345.
• Mayo Clinic. “Gallbladder disease: Symptoms and causes.” Updated 2023. https://www.mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Gallstones.” 2022. https://www.niddk.nih.gov
• World Health Organization. “Obesity and overweight.” 2022. https://www.who.int
• Cleveland Clinic. “Xanthogranulomatous Cholecystitis.” 2023. https://my.clevelandclinic.org

```